Insight Molecular Diagnostics (IMDX) Long-Term Deferred Tax (2018 - 2019)
Insight Molecular Diagnostics (IMDX) posted Long-Term Deferred Tax of $29.2 million for Q4 2019, up 329.46% sequentially from $6.8 million in Q4 2018, and up 329.46% YoY from $6.8 million in Q4 2018.
Insight Molecular Diagnostics (IMDX) Long-Term Deferred Tax (2018 - 2019) Analysis & Trends
Insight Molecular Diagnostics has reported Long-Term Deferred Tax for 2 years, with the latest figure at $29.2 million in Q4 2019.
- Quarterly Long-Term Deferred Tax rose 329.46% year-over-year to $29.2 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $29.2 million (up 329.46% YoY) and the FY2019 annual result came in at $29.2 million, up 329.46% from the prior year.
- Long-Term Deferred Tax grew to $29.2 million in Q4 2019 per IMDX's latest filing, from $6.8 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $29.2 million in Q4 2019 and troughed at $6.8 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn |
| 10 | Insight Molecular Diagnostics | 172.42 Mn | 143.49 Mn | 15,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 29.20 Mn |
| Dec 31, 2018 | 6.80 Mn |